Fig. 3.

Clinical outcomes of ERBB2‐mutated endometrial carcinomas. (A) Progression‐free (PFS) and (B) overall survival (OS) in endometrial carcinomas stratified by ERBB2 mutation (wt, wildtype; mut, mutated) and copy number (non‐amp, non‐amplified; amp, amplified) status. (C) Waterfall plot showing treatment responses to trastuzumab combined with chemotherapy. In EC02, EC22, and EC63, bars showing a 21% increase denotes appearance of new non‐target lesions at first evaluable computed tomography scan performed while on treatment. Specific ERBB2 mutations and histologic subtype are color‐coded as indicated in the legend. (D) Swimmer's plot showing best response to trastuzumab, time on treatment, and time to disease progression. CR, complete response; NE, not evaluable (non‐CR, non‐PD); PD, progression of disease; PR, partial response.